First of all, how are you and your family doing in these COVID19 times?
We are all doing fine, even though it has really been a strange period that has made all of us reconsider life in many aspects.
Denmark has handled the crisis very well and with only a few hundred deaths due to this COVID-19 pandemic. Now the whole country focuses on getting back on track again.
Tell us about you, your career, how you founded or joined this company
I am 47 years old and have been an IT entrepreneur for more or less my whole career. I hold a degree (MSc) in Mathematics and Economy from the University of Copenhagen.
I founded Miiskin in 2015 due to very personal reasons. My partner Rikke struggles with many moles on her skin and is at high risk of developing skin cancer and I needed a system to manage this risk. (Read the full story here: miiskin.com/story)
How does your company innovate?
We create innovative technology to help the user with identifying changes on their skin by using images taken by the user. A change in your skin – either as a new mole or an existing mole changing color, shape or size – can be an early warning sign of skin cancer and should be checked by a dermatologist.
Skin Mapping is our most advanced technology where we support the user with creating a ‘Skin Map’ so that the user can conveniently remember how the skin looked and how the lesions were distributed on the skin.
Video of Skin Mapping :
How the coronavirus pandemic affects your business and how are you coping?
During this crisis, the healthcare professionals very quickly had an acute demand for different telehealth solutions in order to see patients online instead of physical consultations. Within Dermatology and especially remote patient monitoring of the skin and store-and-forward solutions of skin concerns and skin follow-ups, Miiskin is probably the most mature patient centric system in the world to cater for these types of solutions – strengthening and digitizing the doctor-patient relationship. So during this crisis we have had a very strong demand for Miiskin demonstrations and doctors reaching out to us to hear more about our solution for the patient. Currently, Miiskin has been downloaded more than 500,000 times and is recommended by more than 120 hospitals and clinics all over the world.
I believe that this COVID-19 pandemic has really put digital health and telehealth on top of all healthcare professionals priority.
Did you have to make difficult choices and what are the lessons learned?
Internally there have been a lot of choices to make. Changed marketing landscape and opportunities, investors postponing decisions and waiting for the market to stabilize, etc.
One of the most important lessons learned is of course that you need to react quickly and reprioritize all activities to the changed market landscape and seek the opportunity you can identify and postpone others that were obvious three months ago.
How do you deal with stress and anxiety, how do you project yourself and your company in the future?
Being an entrepreneur is always stressful and you never really relax – that is the game. We have been fortunate that we didn’t see any decrease in revenue due to the crisis, so we stick to our plans – even though the market landscape and opportunity dramatically changed.
Ending skin cancer mortality by 2040 is still our bold mission and nothing during this crisis has changed this goal – I strongly believe that technology is a very vital part of the solution.
Who are your competitors? And how do you plan to stay in the game?
We are already in the game and are here to defend our position as the most trusted and recommended app technology to be used in between your physical doctor consultation and we are proud that more than 120 hospitals and clinics recommend Miiskin to their patient at risk.
Some of our competitors are Meta Optima and UMSkinCheck.